Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses advancements in small RNA (siRNA) drug development, particularly in the context of cardiovascular disease treatment and metabolic disorders [1][3][12]. Core Insights and Arguments - **Inclisiran as a Leading siRNA Drug**: Inclisiran demonstrates significant lipid-lowering effects similar to vaccines, requiring administration only twice a year, enhancing patient compliance [1][3]. - **Mechanism of Action**: siRNA not only clears existing target proteins but also inhibits the future production of these proteins, such as PCSK9, providing a more durable treatment effect compared to monoclonal antibodies [1][4][6]. - **Safety and Efficacy**: siRNA is considered safer than gene editing techniques as it does not alter DNA, thus minimizing risks associated with off-target effects and ethical concerns [5][6]. - **Sales Growth of Novartis' PCSK9 siRNA Product**: The product has seen rapid sales growth due to its ability to target liver cells and provide long-lasting effects, with injection intervals of up to six months or even a year [6][12]. - **Challenges in siRNA Delivery**: Effective delivery remains a significant challenge, with the Galenic system being the most mature and clinically validated for liver-targeted delivery [7][19]. - **Potential in Metabolic Weight Loss**: siRNA technology shows promise in metabolic weight loss, but further research is needed to confirm its effectiveness [8][20]. Additional Important Content - **Targeting Cholesterol and Triglycerides**: ANGPTL4 and APOC3 are highlighted as key targets for cholesterol and triglyceride management, respectively, with a focus on achieving cardiovascular benefits [8][10]. - **LPA and LDL in Cardiovascular Risk**: High levels of LPA can indicate cardiovascular risk even when LDL levels are low, suggesting that both should be targeted for optimal cardiovascular health [10]. - **Combination Therapy Potential**: Combining siRNA with statins or other oral medications can significantly enhance lipid-lowering effects, but requires careful monitoring of biochemical indicators for safety [14][15]. - **Long-term Patient Management**: Regular monitoring of biochemical markers is crucial for patients on long-term lipid-lowering therapies, especially in populations with higher intolerance to statins [15][16]. - **Future of siRNA in Clinical Practice**: siRNA drugs could potentially become first-line treatments if they demonstrate sufficient efficacy and safety through large-scale clinical trials [12][13]. Conclusion - The siRNA technology landscape is evolving, with significant potential in treating cardiovascular diseases and metabolic disorders. However, challenges in delivery systems and the need for extensive clinical validation remain critical for its future success in clinical applications [17][23].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任 何損失承擔任何責任。 自願公告 YJH-012 注射液獲得藥物臨床試驗批准通知書 近日，麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.*（「本公司」，連同其 附屬公司統稱為「本集團」）收到國家藥品監督管理局核准簽發的《藥物臨床試驗批准通知 書》（通知書編號：2025LP01629），批准 YJH-012 注射液開展臨床試驗。現將有關詳情公 告如下： 藥物臨床試驗批准通知書的主要內容 藥物名稱：YJH-012 注射液 劑型：注射劑 申請事項：臨床試驗申請 註冊分類：化學藥品 1 類 申請人：麗珠醫藥集團股份有限公司 審批結論：根據《中華人民共和國藥品管理法》及有關規定，經審查，2025 年 4 月 14 日受 理的 YJH-012 注射液臨床試驗申請符合藥品註冊的有關要求，同意本品開展痛風適應症臨 床試驗。 1 藥品研發及相關情況 YJH-012 注射液是本公司與佑嘉（杭州）生物醫藥 ...